Certara (NASDAQ:CERT) Price Target Cut to $14.00 by Analysts at Barclays

Certara (NASDAQ:CERT) had its price objective trimmed by Barclays from $16.00 to $14.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Robert W. Baird decreased their price objective on shares of Certara from $19.00 to $18.00 and set a neutral rating for the company in a research report on Wednesday, August 7th. UBS Group raised Certara from a neutral rating to a buy rating and set a $16.00 price objective for the company in a research report on Friday, September 27th. JMP Securities reiterated a market perform rating on shares of Certara in a report on Wednesday, July 10th. Finally, KeyCorp decreased their target price on Certara from $23.00 to $20.00 and set an overweight rating for the company in a research note on Thursday, July 11th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus price target of $17.08.

Certara Trading Down 0.3 %

NASDAQ:CERT opened at $11.21 on Tuesday. Certara has a 12-month low of $10.35 and a 12-month high of $19.87. The firm has a market cap of $1.80 billion, a PE ratio of -28.74, a price-to-earnings-growth ratio of 5.40 and a beta of 1.49. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The stock has a fifty day moving average price of $11.71 and a 200 day moving average price of $14.50.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. During the same quarter in the previous year, the business posted $0.10 EPS. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. Sell-side analysts anticipate that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Transactions at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Hedge Funds Weigh In On Certara

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wasatch Advisors LP increased its position in shares of Certara by 23.4% in the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after buying an additional 932,598 shares in the last quarter. Geneva Capital Management LLC grew its stake in Certara by 15.1% in the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after acquiring an additional 579,349 shares during the last quarter. Clearbridge Investments LLC increased its holdings in Certara by 0.8% during the 1st quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock valued at $74,617,000 after acquiring an additional 32,846 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Certara by 9.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after acquiring an additional 273,095 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Certara by 9.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock worth $38,418,000 after acquiring an additional 248,448 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.